The primary objective of the trial is to determine the maximum tolerated dose (MTD), dose limiting toxicity (DLT), and safety profile of Reolysin when administered intratumourally to patients
Effective upon regulatory approval of golimumab in the EU, the revised agreement will extend the duration of Schering-Plough’s rights to exclusively market Remicade in its current marketing territories
The Department of Health and Human Services (HHS) granted permission because the company has fulfilled a number of significant milestones in the contract. The income will be recognized
The trial is designed to assess the safety, tolerability and cognitive effects of three doses of MEM 3454 in patients with cognitive impairment associated with schizophrenia (CIAS). The
Use of Helixate FS in conjunction with CSL Behring’s new HeliTrax system can improve patient-physician communication and therapy management. The HeliTrax system combines an Internet-based encrypted database for
Draximage has granted GE Healthcare the exclusive right to market, distribute and sell its generic Draximage Sestamibi in the US market through its US and Canadian radiopharmacy network,
The study will evaluate approximately 340 patients with mild to moderate Alzheimer’s disease. Approximately 65 sites in North America are expected to participate in the program. The study
Under the terms of the new agreement Lundbeck obtains global exclusive rights to Desmoteplase (now including North America) with full control of development and commercialization of the drug
The financial terms of the license agreement consist of an up-front license fee payment to be made by Alphatec to Progressive; testing, design, regulatory and sales milestone payments
Xibrom is a topical non-steroidal anti-inflammatory compound for the treatment of ocular inflammation and pain. Xibrom, approved in 2005, is the first and only FDA-approved twice-daily NSAID for
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.